Transplantation and cellular therapy for older adults—The MSK approach Review

  


Authors: Lin, R. J.; Dahi, P. B.; Korc-Grodzicki, B.; Shahrokni, A.; Jakubowski, A. A.; Giralt, S. A.
Review Title: Transplantation and cellular therapy for older adults—The MSK approach
Abstract: Purpose of Review: Hematologic malignances more commonly affect older individuals and often present with advanced, higher risk disease than younger patients. Allogeneic and autologous hematopoietic cell transplantation is well-established treatment modalities with curative potential following either frontline treatments for these diseases or salvage therapy in the relapsed or refractory setting. More recently, novel cellular immunotherapy such as chimeric antigen receptor T-cell therapy has been shown to lead to high response rate and durable remission in many patients with advanced blood cancers. Recent Findings: Given unique characteristics of older patients, how best to deliver these higher-intensity and time sensitive treatment modalities for them remains challenging. Moreover, their short-term and potential long-term impact on their functional status, cognitive status, and quality of life may be significant considerations for many older patients. All these issues contributed to the lack of access and significant underutilization of these potential curative treatment strategies. Summary: In this review, we present up to date evidence to support potential benefits of transplantation and cellular therapy for older adults, their steady improving outcomes, and most importantly, highlight the use of geriatric assessment to help select appropriate older patients and optimize them prior to and following transplantation and cellular therapy. We specifically describe our approach at Memorial Sloan Kettering Cancer Center and encouraging early results from its implementation. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.
Keywords: aged; transplantation, homologous; salvage therapy; disease free survival; cytarabine; follow up; t lymphocyte; progression free survival; quality of life; hematopoietic stem cell transplantation; cancer therapy; risk factor; depression; hematologic malignancy; myelodysplastic syndrome; hematologic neoplasms; immunotherapy; daunorubicin; cognition; distress syndrome; chimeric antigen receptor; cell therapy; cognitive defect; transplantation, autologous; visual impairment; hearing impairment; adoptive immunotherapy; immunotherapy, adoptive; allotransplantation; hematologic disease; cell transplantation; allogeneic hematopoietic cell transplantation; autologous hematopoietic cell transplantation; autotransplantation; midostaurin; resilience; acute myeloid leukemia; procedures; treosulfan; geriatric disorder; frailty; gemtuzumab; undertreatment; humans; human; article; sarcopenia; venetoclax; enasidenib; ivosidenib; chimeric antigen receptor t-cell therapy; electronic rapid fitness assessment; geriatric assessment and management
Journal Title: Current Hematologic Malignancy Reports
Volume: 19
Issue: 2
ISSN: 1558-8211
Publisher: Springer  
Date Published: 2024-04-01
Start Page: 82
End Page: 91
Language: English
DOI: 10.1007/s11899-024-00725-y
PUBMED: 38332462
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85184923450&doi=10.1007%2fs11899-024-00725-y&partnerID=40&md5=598d4d359619d98df46309fa312df8de
Notes: The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF -- Corresponding author is MSK author: Richard J. Lin -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Beatriz Korc-Grodzicki
    128 Korc-Grodzicki
  2. Sergio Andres Giralt
    1050 Giralt
  3. Ann Jakubowski
    455 Jakubowski
  4. Parastoo Bahrami Dahi
    294 Dahi
  5. Armin Shahrokni
    132 Shahrokni
  6. Richard Jirui Lin
    124 Lin
Related MSK Work